Saturday, August 22, 2009 9:27:53 PM
We all know why the longs post. They want to buy low and sell high. It is true, that the stock will not stay up until there is a big pharma deal. Everyone knows how long it takes to get something FDA approved. I do find the longs much more informative than the naysayers. The naysayers do have some points about promises made and promises gone by. But the recent headlines clearly show this is not a scam. It is real, and just a matter of time. Who knows when, but it feels soon.
But why go negative? Can the nay posters make money trying to scare this board of people out of their stock? Maybe a few. But is it worth that kind of time? I think not. It is a very short lived game, no pun intended. Yet the naysayers are here for the long haul. Why is that?
What would be the motive to bash a very promising drug development company for the long haul? Well here’s one:
A prospective big pharma client (who prefers nondisclosure) would like to make money on both ends. Once when the stock goes up on the PR disclosing the big pharma company and the deal and again when the drug hits the market. So, they hire folks to bash while they buy up the stock for a song. They are the same old names with the same old tired points. But they have deep pockets and can wait a long time. They can sell on news that is not a big pharma deal because they know the stock will go right back down in a few days and they can buy even more stock.
So, now we all know the equation. Sell on news that is not a big phama deal. Keep buying when its down.
Truth of the matter is, all this is liars poker anyway. So, I agree, “show me the money.”
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM